Issues in cervical cancer incidence and treatment in HIV

Mark H. Einstein, Rébécca Phaëton

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose of review: Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. Recent findings: The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. Summary: The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalCurrent Opinion in Oncology
Volume22
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Uterine Cervical Neoplasms
HIV
Incidence
Therapeutics
Highly Active Antiretroviral Therapy
Papillomavirus Infections
Chemoradiotherapy
Standard of Care
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Developed Countries
Developing Countries
Registries
Immune System
Patient Care
Pharmaceutical Preparations

Keywords

  • antiretroviral therapy
  • cervical cancer
  • HIV
  • human papillomavirus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Issues in cervical cancer incidence and treatment in HIV. / Einstein, Mark H.; Phaëton, Rébécca.

In: Current Opinion in Oncology, Vol. 22, No. 5, 09.2010, p. 449-455.

Research output: Contribution to journalArticle

Einstein, Mark H. ; Phaëton, Rébécca. / Issues in cervical cancer incidence and treatment in HIV. In: Current Opinion in Oncology. 2010 ; Vol. 22, No. 5. pp. 449-455.
@article{5d27b14b718c4068af7ad9da7fd59fba,
title = "Issues in cervical cancer incidence and treatment in HIV",
abstract = "Purpose of review: Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. Recent findings: The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. Summary: The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.",
keywords = "antiretroviral therapy, cervical cancer, HIV, human papillomavirus",
author = "Einstein, {Mark H.} and R{\'e}b{\'e}cca Pha{\"e}ton",
year = "2010",
month = "9",
doi = "10.1097/CCO.0b013e32833cff4f",
language = "English (US)",
volume = "22",
pages = "449--455",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Issues in cervical cancer incidence and treatment in HIV

AU - Einstein, Mark H.

AU - Phaëton, Rébécca

PY - 2010/9

Y1 - 2010/9

N2 - Purpose of review: Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. Recent findings: The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. Summary: The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.

AB - Purpose of review: Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. Recent findings: The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. Summary: The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.

KW - antiretroviral therapy

KW - cervical cancer

KW - HIV

KW - human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=77955426522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955426522&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32833cff4f

DO - 10.1097/CCO.0b013e32833cff4f

M3 - Article

VL - 22

SP - 449

EP - 455

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -